Ethacrynic acid
Edecrin (ethacrynic acid) is a small molecule pharmaceutical. Ethacrynic acid was first approved as Edecrin on 1982-01-01. It is used to treat ascites, chronic kidney failure, edema, heart failure, and hypertension amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
| respiratory tract diseases | D012140 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Edecrin (generic drugs available since 2016-06-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethacrynic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EDECRIN | Bausch Health Companies | N-016092 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| edecrin sodium edecrin | New Drug Application | 2020-08-31 |
| ethacrynic acid | ANDA | 2023-03-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ascites | HP_0001541 | D001201 | R18 |
| chronic kidney failure | EFO_0003884 | D007676 | N18.6 |
| edema | — | D004487 | R60.9 |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| liver cirrhosis | EFO_0001422 | D008103 | K74.0 |
| nephrotic syndrome | EFO_0004255 | D009404 | N04 |
| pulmonary edema | EFO_1001134 | D011654 | J81 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | 2 | 4 | 3 | 2 | 6 | 15 | |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | 1 | — | 1 | 1 | 3 |
| Assisted reproductive techniques | D027724 | — | — | 1 | 1 | 1 | 3 | ||
| Fertilization in vitro | D005307 | — | — | — | 2 | — | 2 | ||
| Embryo loss | D020964 | — | — | — | 1 | — | 1 | ||
| Aneuploidy | D000782 | — | — | — | 1 | — | 1 | ||
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | 1 | — | 1 |
| Anovulation | D000858 | — | — | — | 1 | — | 1 | ||
| Hyperandrogenism | D017588 | — | — | — | 1 | — | 1 | ||
| Healthy volunteers/patients | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fertility | D005298 | — | — | — | — | 1 | 1 | ||
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
| Pregnancy outcome | D011256 | — | — | — | — | 1 | 1 | ||
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ETHACRYNIC ACID |
| INN | etacrynic acid |
| Description | Etacrynic acid is an aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor. It has a role as an ion transport inhibitor, an EC 2.5.1.18 (glutathione transferase) inhibitor and a loop diuretic. It is an aromatic ether, a monocarboxylic acid, an aromatic ketone and a dichlorobenzene. It is functionally related to an acetic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl |
Identifiers
| PDB | — |
| CAS-ID | 58-54-8 |
| RxCUI | 4109 |
| ChEMBL ID | CHEMBL456 |
| ChEBI ID | 4876 |
| PubChem CID | 3278 |
| DrugBank | DB00903 |
| UNII ID | M5DP350VZV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,491 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
341 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more